BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30728152)

  • 1. GM-CSF Promotes Antitumor Immunity by Inducing Th9 Cell Responses.
    Kim IK; Koh CH; Jeon I; Shin KS; Kang TS; Bae EA; Seo H; Ko HJ; Kim BS; Chung Y; Kang CY
    Cancer Immunol Res; 2019 Mar; 7(3):498-509. PubMed ID: 30728152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in GM-CSF-based cancer immunotherapy.
    Yan WL; Shen KY; Tien CY; Chen YA; Liu SJ
    Immunotherapy; 2017 Mar; 9(4):347-360. PubMed ID: 28303764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
    Dang Y; Wagner WM; Gad E; Rastetter L; Berger CM; Holt GE; Disis ML
    Clin Cancer Res; 2012 Jun; 18(11):3122-31. PubMed ID: 22510348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF.
    Goyal G; Wong K; Nirschl CJ; Souders N; Neuberg D; Anandasabapathy N; Dranoff G
    Cancer Immunol Res; 2018 Jun; 6(6):723-732. PubMed ID: 29669721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
    Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
    Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells.
    Ferlazzo G; Klein J; Paliard X; Wei WZ; Galy A
    J Immunother; 2000 Jan; 23(1):48-58. PubMed ID: 10687137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro].
    He SB; Sun K; Wang L; Li DC; Zhang YY
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):410-4. PubMed ID: 20819479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy.
    Alters SE; Gadea JR; Holm B; Lebkowski J; Philip R
    J Immunother; 1999 May; 22(3):229-36. PubMed ID: 10335482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor induces the differentiation of murine erythroleukaemia cells into dendritic cells.
    Cao X; Zhao Y; Yu Y; Wang Y; Zhang M; Zhang W; Wang J
    Immunology; 1998 Sep; 95(1):141-7. PubMed ID: 9767469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foxo1 and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of T
    Bi E; Ma X; Lu Y; Yang M; Wang Q; Xue G; Qian J; Wang S; Yi Q
    Sci Signal; 2017 Oct; 10(500):. PubMed ID: 29018172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
    Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern.
    Ebner S; Hofer S; Nguyen VA; Fürhapter C; Herold M; Fritsch P; Heufler C; Romani N
    J Immunol; 2002 Jun; 168(12):6199-207. PubMed ID: 12055233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
    Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
    Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types.
    Hong IS
    Exp Mol Med; 2016 Jul; 48(7):e242. PubMed ID: 27364892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.